Clinical Biochemistry — MCQs

Clinical Biochemistry Indian Medical PG Practice Questions and MCQs

Question 51: Troponin T is elevated in which of the following conditions?

A. Myxedema
B. Myocardial infarction (Correct Answer)
C. Thyrotoxicosis
D. Viral hepatitis

Explanation: ### Explanation **Correct Answer: B. Myocardial Infarction** **Why it is correct:** Cardiac Troponins (cTnI and cTnT) are highly specific and sensitive regulatory proteins of the myofibrillar contractile apparatus. In the event of **Myocardial Infarction (MI)**, cardiomyocyte necrosis leads to the leakage of these proteins into the bloodstream. Troponin T is considered a "gold standard" biomarker for diagnosing acute coronary syndrome because it rises within 3–4 hours of injury, peaks at 12–24 hours, and remains elevated for up to 10–14 days, providing a wide diagnostic window. **Why the other options are incorrect:** * **A & C (Myxedema and Thyrotoxicosis):** These are thyroid disorders. While severe hypothyroidism (Myxedema) can occasionally cause a mild elevation in CK-MB due to reduced clearance or skeletal muscle involvement, Troponin T is specific to cardiac muscle and is not a marker for thyroid dysfunction. * **D (Viral Hepatitis):** This is an inflammatory condition of the liver. The characteristic biomarkers for hepatitis are transaminases (ALT/AST) and Bilirubin. Troponin T is not found in hepatocytes and remains unaffected by liver pathology. **High-Yield Clinical Pearls for NEET-PG:** * **Troponin I vs. T:** Troponin I is considered slightly more cardio-specific than Troponin T (which can rarely be elevated in end-stage renal disease or chronic skeletal muscle myopathy). * **Sequence of Elevation:** Myoglobin is the *earliest* marker to rise (1–2 hours), but Troponin is the most *specific*. * **Re-infarction:** CK-MB is the preferred marker to detect a second MI occurring within a week of the first, as Troponins stay elevated for too long to distinguish a new event. * **Rule of Thumb:** Any condition causing "myocyte necrosis" (e.g., myocarditis, severe heart failure, or pulmonary embolism) can elevate Troponins, but in the context of acute chest pain, it is diagnostic for MI.

Question 52: C peptide reflects:

A. Thyroxine
B. Parathormone
C. Insulin (Correct Answer)
D. Growth hormone

Explanation: **Explanation:** **Why Insulin is Correct:** Insulin is synthesized in the pancreatic beta cells as a precursor molecule called **Preproinsulin**. After the removal of the signal peptide, it becomes **Proinsulin**. Proinsulin consists of three chains: the A-chain, the B-chain, and a connecting segment known as the **C-peptide** (Connecting peptide). Inside the secretory granules, proinsulin is cleaved by endopeptidases into equimolar amounts of mature **Insulin** and **C-peptide**. Both are secreted into the portal circulation together. Therefore, C-peptide levels serve as a reliable marker of **endogenous insulin production** and pancreatic beta-cell function. **Why Other Options are Incorrect:** * **Thyroxine (T4):** Produced by the thyroid gland; its synthesis involves thyroglobulin iodination, not a prohormone cleavage involving C-peptide. * **Parathormone (PTH):** Produced by the parathyroid glands; while it has a "Pre-pro" stage, it does not release a C-peptide fragment used in clinical monitoring. * **Growth Hormone (GH):** A single-chain polypeptide secreted by the anterior pituitary; it does not involve C-peptide during its processing. **High-Yield Clinical Pearls for NEET-PG:** 1. **Half-life:** C-peptide has a longer half-life (approx. 30 mins) than insulin (approx. 5 mins), making it a more stable indicator of insulin secretion. 2. **Exogenous vs. Endogenous:** In cases of **Factitious Hypoglycemia** (self-injection of insulin), insulin levels will be high, but C-peptide levels will be **low**. In an **Insulinoma**, both insulin and C-peptide levels will be **high**. 3. **Type 1 vs. Type 2 Diabetes:** C-peptide is used to differentiate the two; it is typically low/absent in Type 1 DM and normal/high in early Type 2 DM. 4. **Metabolism:** Unlike insulin, C-peptide does not undergo significant first-pass metabolism by the liver; it is primarily cleared by the **kidneys**.

Question 53: Which fraction of CPK is elevated in a myocardial infarction?

A. MM fraction
B. MB fraction (Correct Answer)
C. BB fraction
D. MM and BB fractions

Explanation: **Explanation:** Creatine Phosphokinase (CPK), also known as Creatine Kinase (CK), is a dimeric enzyme consisting of two subunits: **M (Muscle)** and **B (Brain)**. These subunits combine to form three distinct isoenzymes, each specific to different tissues. **1. Why Option B is Correct:** The **CPK-MB (MB fraction)** is primarily found in the **myocardium** (heart muscle). Following a myocardial infarction (MI), damaged cardiac myocytes leak this enzyme into the bloodstream. CPK-MB levels typically begin to rise 4–6 hours after the onset of chest pain, peak at 12–24 hours, and return to baseline within 48–72 hours. This makes it a specific marker for acute myocardial injury. **2. Why Other Options are Incorrect:** * **Option A (MM fraction):** CPK-MM is the predominant isoenzyme in **skeletal muscle** (99%) and the heart (80%). While it rises in MI, it is highly non-specific as it also increases due to strenuous exercise, intramuscular injections, or muscular dystrophy. * **Option C (BB fraction):** CPK-BB is found mainly in the **brain**, lungs, and gastrointestinal tract. It rarely appears in the blood because it cannot cross the blood-brain barrier; its elevation suggests CNS damage or certain tumors. * **Option D:** This is incorrect as the BB fraction is not associated with cardiac injury. **NEET-PG High-Yield Pearls:** * **Gold Standard:** While CPK-MB was historically the marker of choice, **Cardiac Troponins (I and T)** are now the "Gold Standard" due to higher sensitivity and specificity. * **Re-infarction:** CPK-MB is still clinically valuable for detecting **re-infarction** because its levels normalize quickly (within 3 days), whereas Troponins remain elevated for up to 10–14 days. * **Electrophoresis:** On electrophoresis, the mobility order is: **BB (fastest/anodal) > MB > MM (slowest/cathodal).**

Question 54: Reducing sugar in urine can be detected by which of the following tests?

A. Benedict's test
B. Fehling's solution
C. Glucose-oxidase test
D. All of the above (Correct Answer)

Explanation: ### Explanation The detection of sugar in urine is a fundamental clinical biochemistry tool used to screen for metabolic disorders like Diabetes Mellitus. **1. Benedict’s Test & Fehling’s Solution:** Both are **non-specific copper reduction tests**. They rely on the ability of reducing sugars (glucose, fructose, galactose, lactose, etc.) to reduce cupric ions ($Cu^{2+}$) in an alkaline medium to cuprous oxide ($Cu_2O$), resulting in a color change from blue to green, yellow, or brick red. While Benedict’s is more stable and commonly used in labs, both detect the presence of any reducing substance. **2. Glucose-Oxidase Test:** Unlike the copper reduction tests, this is a **specific enzymatic test** (often used in urine dipsticks). The enzyme glucose oxidase reacts specifically with glucose to produce gluconic acid and hydrogen peroxide. The peroxide then reacts with a chromogen to produce a color change. Because it only reacts with glucose, it will not give a positive result for other reducing sugars like galactose or lactose. **Why "All of the above" is correct:** The question asks which tests can detect "reducing sugar." Since glucose is the most common reducing sugar in urine, all three methods—the non-specific chemical tests (Benedict’s and Fehling’s) and the specific enzymatic test (Glucose-oxidase)—will successfully detect it. ### Clinical Pearls for NEET-PG: * **False Positives in Benedict’s Test:** Can be caused by non-sugar reducing substances like Vitamin C (Ascorbic acid), salicylates, and uric acid. * **Galactosemia Screening:** In infants, if Benedict’s test is positive but the Glucose-oxidase test (dipstick) is negative, it strongly suggests the presence of a non-glucose reducing sugar, most commonly **galactose**. * **Sensitivity:** The Glucose-oxidase method is highly sensitive and specific, whereas Benedict’s is a semi-quantitative screening tool.

Question 55: What is the preferred biomarker for acute myocardial disease?

A. Serum LDH
B. Cardiac Troponin I and T (Correct Answer)
C. CK-MB
D. CK-BB

Explanation: **Explanation:** **Cardiac Troponins (cTnI and cTnT)** are the gold standard and preferred biomarkers for acute myocardial infarction (AMI) due to their **high cardiac specificity** and **superior sensitivity**. Unlike other enzymes, troponins are structural proteins of the cardiac myofibrils. Following myocardial injury, they are released into the bloodstream, remaining elevated for 7–14 days, which allows for both early and late diagnosis. **Analysis of Incorrect Options:** * **CK-MB (Creatine Kinase-MB):** While specific to the heart, it is less sensitive than troponins. Its primary utility now is in detecting **re-infarction** because it returns to baseline within 48–72 hours, whereas troponins remain elevated. * **Serum LDH (Lactate Dehydrogenase):** This is a non-specific marker found in many tissues (RBCs, liver, muscle). LDH-1/LDH-2 "flipped ratio" was used historically but is now obsolete due to its late rise and lack of specificity. * **CK-BB:** This isoenzyme is primarily found in the **brain** and smooth muscles; it has no clinical utility in diagnosing myocardial disease. **High-Yield Clinical Pearls for NEET-PG:** * **Earliest Marker:** Myoglobin is the earliest to rise (1–3 hours) but is highly non-specific. * **Most Specific Marker:** Cardiac Troponin I (cTnI) is considered more cardiac-specific than cTnT (which can occasionally rise in renal failure or skeletal muscle injury). * **Time Frame:** Troponins rise within 3–6 hours, peak at 12–24 hours, and persist for up to 2 weeks. * **Rule of Thumb:** If a patient presents with chest pain, the first-line biochemical investigation is always Cardiac Troponin.

Question 56: Serum alkaline phosphatase level increases in:

A. Hypothyroidism
B. Carcinoma of the prostate
C. Hyperparathyroidism (Correct Answer)
D. Myocardial infarction

Explanation: **Explanation:** **Hyperparathyroidism (Correct Answer):** Alkaline Phosphatase (ALP) is a marker of **osteoblastic activity**. In hyperparathyroidism, elevated Parathyroid Hormone (PTH) stimulates osteoclasts to resorb bone. However, bone resorption is coupled with compensatory osteoblastic activity to repair the bone matrix. This increased osteoblastic turnover leads to the release of ALP into the circulation. It is a classic biochemical finding in primary, secondary, and tertiary hyperparathyroidism, especially when bone involvement (Osteitis fibrosa cystica) is present. **Analysis of Incorrect Options:** * **Hypothyroidism:** This condition is typically associated with **decreased** ALP levels due to reduced bone turnover and metabolic rate. * **Carcinoma of the Prostate:** The primary marker for prostate cancer is Prostate-Specific Antigen (PSA). While metastatic prostate cancer to the bone (osteoblastic metastases) can raise ALP, the most specific enzyme associated with prostate cancer (historically and in exams) is **Acid Phosphatase (ACP)**. * **Myocardial Infarction:** The cardiac biomarkers of choice are Troponins and CK-MB. Historically, LDH and AST were used, but ALP has no diagnostic role in MI as it is not found in significant quantities in cardiac muscle. **NEET-PG High-Yield Pearls:** * **Physiological Increase in ALP:** Seen in growing children (bone growth) and the third trimester of pregnancy (placental isoenzyme). * **Pathological Increase:** Most commonly seen in **Cholestasis** (obstructive jaundice) and **Bone diseases** (Paget’s disease, Rickets, Osteomalacia, and Hyperparathyroidism). * **Highest ALP Levels:** Characteristically seen in **Paget’s disease of bone**. * **Low ALP Levels:** Seen in Hypophosphatasia, Zinc deficiency, and Hypothyroidism.

Question 57: Insulin storage in the body requires which ion?

A. Cu
B. Zn (Correct Answer)
C. Mo
D. Se

Explanation: **Explanation:** **Correct Answer: B. Zn (Zinc)** Insulin is synthesized in the pancreatic **beta cells** as proinsulin. During its maturation and storage within secretory granules, insulin molecules aggregate to form **hexamers**. This hexameric structure is stabilized by the coordination of **two Zinc (Zn²⁺) ions**. This storage form is highly stable and protects the insulin peptide from degradation before it is secreted into the bloodstream. Once released into the portal circulation, the hexamer dissociates into active monomers. **Analysis of Incorrect Options:** * **A. Cu (Copper):** Copper is a vital cofactor for enzymes like Cytochrome c oxidase and Superoxide Dismutase (SOD), but it plays no role in insulin stabilization. * **C. Mo (Molybdenum):** This is a cofactor for enzymes such as Xanthine oxidase and Sulfite oxidase. * **D. Se (Selenium):** Selenium is essential for the antioxidant enzyme **Glutathione peroxidase** and the conversion of T4 to T3 (Deiodinase), but not for insulin storage. **High-Yield Clinical Pearls for NEET-PG:** * **C-Peptide:** It is stored and released in equimolar amounts with insulin. It serves as a marker for endogenous insulin production (useful in distinguishing Type 1 DM from Type 2 DM or Factitious Hypoglycemia). * **Zinc Deficiency:** Can lead to impaired glucose tolerance due to decreased insulin storage and structural stability. * **Acrodermatitis Enteropathica:** An autosomal recessive disorder of zinc absorption characterized by periorificial dermatitis, alopecia, and diarrhea. * **Insulin Formulations:** Modern long-acting insulins (like NPH) often utilize zinc and protamine to delay absorption from the subcutaneous site.

Question 58: An individual has a fasting blood glucose concentration of 115 mg/dL on three occasions. What is your conclusion?

A. Normal
B. Diabetic
C. Impaired glucose tolerance (Correct Answer)
D. Needs further evaluation by other biochemical tests

Explanation: ### Explanation The diagnosis of glycemic status is based on standardized criteria set by the WHO and ADA. This question tests your knowledge of the **Fasting Plasma Glucose (FPG)** thresholds. **1. Why "Impaired Glucose Tolerance" (Prediabetes) is correct:** According to current guidelines, the classification for Fasting Plasma Glucose is: * **Normal:** < 100 mg/dL * **Impaired Fasting Glucose (IFG):** 100–125 mg/dL * **Diabetes Mellitus:** ≥ 126 mg/dL A value of **115 mg/dL** falls squarely within the 100–125 mg/dL range. Since this was confirmed on three separate occasions, it consistently indicates a state of "Prediabetes." While the technical term for fasting elevation is "Impaired Fasting Glucose," in the context of many exams (including NEET-PG), this is often grouped under the broader clinical umbrella of **Impaired Glucose Tolerance (IGT)** or Prediabetes. **2. Analysis of Incorrect Options:** * **A. Normal:** Incorrect, as the upper limit for normal fasting glucose is 99 mg/dL. * **B. Diabetic:** Incorrect, as the diagnostic cutoff for diabetes is ≥ 126 mg/dL on two separate occasions. * **D. Needs further evaluation:** While an Oral Glucose Tolerance Test (OGTT) or HbA1c might be done clinically to further assess risk, the *conclusion* based on the provided data is already defined by the diagnostic criteria. **3. High-Yield Clinical Pearls for NEET-PG:** * **HbA1c Cutoffs:** Normal (< 5.7%), Prediabetes (5.7–6.4%), Diabetes (≥ 6.5%). * **2-hour Post-Prandial (OGTT):** Normal (< 140 mg/dL), IGT (140–199 mg/dL), Diabetes (≥ 200 mg/dL). * **Random Blood Sugar:** ≥ 200 mg/dL + classic symptoms of hyperglycemia (polyuria, polydipsia, weight loss) is diagnostic for Diabetes. * **Note:** Always look for "two separate occasions" for a definitive diagnosis unless the patient is in a clear hyperglycemic crisis.

Question 59: A 35-year-old man has fasting and postprandial blood sugar within normal limits, but urine sugar is 3 plus (+++). What is the most likely diagnosis?

A. Renal glycosuria (Correct Answer)
B. Pancreatic insufficiency
C. Alimentary glycosuria
D. High carbohydrate intake

Explanation: **Explanation:** The clinical scenario describes a patient with **normoglycemia** (normal blood sugar) but significant **glycosuria** (glucose in the urine). This is the hallmark of **Renal Glycosuria**. **1. Why Renal Glycosuria is correct:** Under normal physiological conditions, glucose is filtered by the glomerulus and almost completely reabsorbed in the Proximal Convoluted Tubule (PCT) via SGLT-2 transporters. The **Renal Threshold for glucose** is typically **180 mg/dL**. In Renal Glycosuria, there is a functional defect in these transporters or a reduced threshold, causing glucose to be excreted in the urine even when blood glucose levels are well below 180 mg/dL. Since the patient’s fasting and postprandial sugars are normal, the pathology is isolated to the kidneys. **2. Why other options are incorrect:** * **Pancreatic Insufficiency:** This would lead to Diabetes Mellitus due to insulin deficiency. In such cases, glycosuria only occurs because blood glucose levels exceed the renal threshold (Hyperglycemic glycosuria). * **Alimentary Glycosuria:** This occurs when rapid intestinal absorption of glucose causes a transient spike in postprandial blood sugar above the renal threshold (e.g., post-gastrectomy). Here, the postprandial sugar would be abnormally high, which contradicts the question. * **High Carbohydrate Intake:** In a healthy individual, the pancreas compensates with insulin; blood sugar remains within limits, and no glucose appears in the urine. **High-Yield Clinical Pearls for NEET-PG:** * **Fanconi Syndrome:** If renal glycosuria is associated with phosphaturia, aminoaciduria, and uricosuria, suspect generalized PCT dysfunction. * **Pregnancy:** A physiological decrease in the renal threshold for glucose is common, often leading to benign glycosuria. * **SGLT-2 Inhibitors (e.g., Dapagliflozin):** These drugs pharmacologically induce renal glycosuria to treat Type 2 Diabetes.

Question 60: Inactivation of cortisol into cortisone occurs mainly in which organ?

A. Lungs
B. Liver
C. Adrenals
D. Kidney (Correct Answer)

Explanation: ### Explanation The conversion of active **cortisol** to inactive **cortisone** is a protective mechanism primarily occurring in the **Kidney**. **1. Why Kidney is the Correct Answer:** The kidney expresses high levels of the enzyme **11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2)**. This enzyme inactivates cortisol into cortisone. This is crucial because cortisol has a high affinity for **Mineralocorticoid Receptors (MR)** in the distal nephron. Without this inactivation, the high circulating levels of cortisol would overwhelm the MR, leading to excessive sodium retention and potassium loss (mimicking hyperaldosteronism). **2. Why Other Options are Incorrect:** * **Liver:** The liver primarily performs the **reverse** reaction. It contains **11β-HSD type 1**, which converts inactive cortisone back into active cortisol (activation). * **Adrenals:** The adrenal cortex is the site of cortisol **synthesis** (specifically the Zona Fasciculata), not its primary site of inactivation. * **Lungs:** While the lungs possess some metabolic activity, they are not the principal site for the systemic inactivation of cortisol via the 11β-HSD2 pathway. **3. Clinical Pearls for NEET-PG:** * **Apparent Mineralocorticoid Excess (AME):** A genetic deficiency of 11β-HSD2 (or inhibition by **Glycyrrhizic acid** found in **Licorice**) prevents cortisol inactivation. This leads to hypertension, hypokalemia, and metabolic alkalosis despite low aldosterone levels. * **11β-HSD1 (Liver):** Bidirectional but mainly acts as a **reductase** (Cortisone → Cortisol). * **11β-HSD2 (Kidney):** Unidirectional **dehydrogenase** (Cortisol → Cortisone). * **Cortisol vs. Aldosterone:** Cortisol circulates at concentrations ~1000 times higher than aldosterone; hence, 11β-HSD2 is the "gatekeeper" of the mineralocorticoid receptor.

Practice by Chapter

Liver Function Tests

Practice Questions

Kidney Function Tests

Practice Questions

Cardiac Markers and Enzymes

Practice Questions

Pancreatic Function Tests

Practice Questions

Glucose Tolerance Tests

Practice Questions

Lipid Profile and Cardiovascular Risk

Practice Questions

Tumor Markers

Practice Questions

Hormonal Assays and Interpretation

Practice Questions

Electrolytes and Acid-Base Balance Tests

Practice Questions

Cerebrospinal Fluid Analysis

Practice Questions

Point-of-Care Testing

Practice Questions

Quality Control in Clinical Biochemistry

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free